3-TYP, a selective SIRT3 inhibitor, reversed AEDC effect on autophagy, indicating that AEDC inhibited NLRP3 inflammasome activation to ameliorate inflammation-related metabolic disorders by promoting autophagy via SIRT3. Here, NLRP3 is linked to metabolic disease.